SarCNU (2-chloroethyl-3-sarcosinamide-1-nitrosourea): a novel analogue of chloroethylnitrosourea that is transported by the catecholamine uptake2 carrier, which mediates increased cytotoxicity L. C. PanasciDaniela MarcantonioAdrian J. Noë REVIEW Pages: 505 - 508
AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies S. WebberCharlotte A. BartlettBhasker V. Shetty ORIGINAL ARTICLE Pages: 509 - 517
The integrity of cisplatin in aqueous and plasma ultrafiltrate media studied by 195Pt and 15N nuclear magnetic resonance K. M. BrièreRakesh GoelIan C. P. Smith ORIGINAL ARTICLE Pages: 518 - 524
In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines Y. KanoMiyuki AkutsuYasuo Yazawa ORIGINAL ARTICLE Pages: 525 - 530
Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies S. M. SugarmanY. Y. ZouRoman Perez-Soler ORIGINAL ARTICLE Pages: 531 - 538
Penetration of intravesical doxorubicin in human bladders M. G. WientjesRobert A. BadalamentJessie L.-S. Au ORIGINAL ARTICLE Pages: 539 - 546
Intracellular localization and intercellular heterogeneity of the human DNA repair protein O6-methylguanine-DNA methyltransferase M. BelanichTerri RandallDaniel B. Yarosh ORIGINAL ARTICLE Pages: 547 - 555
On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance Yan-Ping HuSophie JarillonJ. Robert ORIGINAL ARTICLE Pages: 556 - 560
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies A. M. HusseinWilliam P. PetrosWilliam P. Peters ORIGINAL ARTICLE Pages: 561 - 568
Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus G. F. FlemingEverett E VokesM Eileen Dolan ORIGINAL ARTICLE Pages: 569 - 573
A comparison of hyperthermia cisplatin sensitization in human ovarian carcinoma and glioma cell lines sensitive and resistant to cisplatin treatment G. P. RaaphorstS. DojaC. E. Ng ORIGINAL ARTICLE Pages: 574 - 580
A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer N. J. MeropolYousef M. RustumPatrick J. Creaven ORIGINAL ARTICLE Pages: 581 - 586
A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer K. SakaiGoro KosakiAkira Oshima ORIGINAL ARTICLE Pages: 587 - 592
Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine Michael P. GoslandMark N. GillespieS. M. Aziz ORIGINAL ARTICLE Pages: 593 - 600
Transforming growth factor-β in in vivo resistance B. A. TeicherSylvia A. HoldenGuan Chen ORIGINAL ARTICLE Pages: 601 - 609
Carboplatin and vinorelbine in advanced non-small-cell lung cancer P. PronzatoErmanno GhioAntonella Vigani CLINICAL TRIAL REPORT Pages: 610 - 612
Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer C. GridelliAntonio RossiAngelo Raffaele Bianco CLINICAL TRIAL REPORT Pages: 613 - 615
Is there a circadian variation in plasma concentrations of etoposide given by prolonged continuous infusion? Yuichi AndoHironobu MinamiK. Shimokata SHORT COMMUNICATION Pages: 616 - 618